This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bloomston, M. Articles by Yeatman, T. J. Search for Related Content PubMed PubMed Citation Articles by Bloomston, M. Articles by Yeatman, T. J.

Fibrinogen Overexpression in Pancreatic Cancer Identified by Large-scale Proteomic Analysis of Serum Samples

¹ Division of Surgical Oncology, James Cancer Hospital and Solove Research Institute; ² Department of Pathology, Ohio State University, Columbus, Ohio; ³ Laboratory of Immunopathology, National Institute of Allergy and Infectious Diseases, NIH, Rockville, Maryland; ⁴ Department of Surgery, University of South Florida; and ⁵ Division of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

Requests for reprints: Timothy J. Yeatman, H. Lee Moffitt Cancer and Research Institute, 12902 Magnolia Drive, SRB-2, Tampa, FL 33612. Phone: 813-979-7292; Fax: 813-632-1433; E-mail: yeatman{at}moffitt.usf.edu.

Detection of serum markers for pancreatic cancer has been elusive. Although CA 19-9 is most commonly used, its sensitivity and specificity are modest. We used large-scale proteomics to identify potential serum markers for pancreatic cancer. Samples were analyzed using high-resolution two-dimensional gel electrophoresis to identify differentially expressed proteins in 32 normal and 30 pancreatic cancer patients. Up to 1,744 protein spots were resolved for each serum sample. Candidate proteins were identified using mass spectrometry. ANOVA was used to identify proteins that could discriminate cancer from normal sera. Serum fibrinogen level was also measured using enzymatic assay. Immunohistochemistry was used to detect fibrinogen in resected pancreatic cancers. One hundred fifty-four proteins were commonly overexpressed in all pancreatic cancers. Nine protein spots (four with identifications by mass spectrometry) could effectively separate cancer from normal controls using cross-validation. These proteins successfully discriminated all pancreatic cancer samples (30 of 30) and 94% of normal (30 of 32) samples. Prominent among these candidates was fibrinogen , which was subsequently confirmed to be overexpressed in pancreatic cancer sera by enzymatic analysis (54.1 ± 64.1 versus 0.0 ± 0.0 mg/dL, P < 0.05) and tissue by immunohistochemistry (67% versus 29%, P < 0.05) relative to normal pancreas. Proteomic analysis combining two-dimensional gel electrophoresis and mass spectrometry successfully identified 154 potential serum markers for pancreatic cancer. Of these, fibrinogen , a protein associated with the hypercoagulable state of pancreatic cancer, discriminated cancer from normal sera. Fibrinogen is a potential tumor marker in pancreatic cancer. (Cancer Res 2006; 66(5): 2592-9)

This article has been cited by other articles:

				W.-L. ZHU, B.-L. FAN, D.-L. LIU, and W.-X. ZHU Abnormal Expression of Fibrinogen Gamma (FGG) and Plasma Level of Fibrinogen in Patients with Hepatocellular Carcinoma Anticancer Res, July 1, 2009; 29(7): 2531 - 2534. [Abstract] [Full Text] [PDF]

				T. Hibi, T. Mori, M. Fukuma, K. Yamazaki, A. Hashiguchi, T. Yamada, M. Tanabe, K. Aiura, T. Kawakami, A. Ogiwara, et al. Synuclein-{gamma} Is Closely Involved in Perineural Invasion and Distant Metastasis in Mouse Models and Is a Novel Prognostic Factor in Pancreatic Cancer Clin. Cancer Res., April 15, 2009; 15(8): 2864 - 2871. [Abstract] [Full Text] [PDF]

				A Masamune, K Kikuta, T Watanabe, K Satoh, M Hirota, S Hamada, and T Shimosegawa Fibrinogen induces cytokine and collagen production in pancreatic stellate cells Gut, April 1, 2009; 58(4): 550 - 559. [Abstract] [Full Text] [PDF]

				T Qi, J Han, Y Cui, M Zong, X Liu, and B Zhu Comparative proteomic analysis for the detection of biomarkers in pancreatic ductal adenocarcinomas J. Clin. Pathol., January 1, 2008; 61(1): 49 - 58. [Abstract] [Full Text] [PDF]

				L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer J. Clin. Oncol., November 20, 2007; 25(33): 5287 - 5312. [Abstract] [Full Text] [PDF]

				R. Chen, T. A. Brentnall, S. Pan, K. Cooke, K. W. Moyes, Z. Lane, D. A. Crispin, D. R. Goodlett, R. Aebersold, and M. P. Bronner Quantitative Proteomics Analysis Reveals That Proteins Differentially Expressed in Chronic Pancreatitis Are Also Frequently Involved in Pancreatic Cancer Mol. Cell. Proteomics, August 1, 2007; 6(8): 1331 - 1342. [Abstract] [Full Text] [PDF]